Hengrui Pharma has lined up Bristol Myers Squibb as its latest partner in a deal worth up to $15.2 billion. The total value of the pact marks one of the largest East-to-West cross-border deals in industry history.
It’s becoming Hengrui Pharma’s world, and some Western drugmakers are just living in it.
China’s largest pharma company, which boasts one of the biggest pipelines …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese…
U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of…
The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui…
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…
Bristol Myers’ alliance with Hengrui ranks as the second-largest licensing pact of its kind since the start of 2025, trailing…
The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition
GSK cuts deal with Sino to broaden reach of hepatitis B drug
Lilly, Gilead lead pharma’s M&A boom
India’s pharma industry is going global. But can it catch up to China?
Hims' sales miss as telehealth competition grows
